Alessandro Inno: A case of a very elderly patient with MET-exon 14 mutant NSCLC with meaningful and durable benefit from first-line tepotinib, with an acceptable safety profile
Quoting Alessandro Inno, on LinkedIn:
”Tepotinib and capmatinib are MET inhibitors approved by European Medicines Agency for patients with metastatic NSCLC harboring MET exon-14 skipping mutations, but only after receiving immunotherapy and/or platinum-based chemotherapy. However, MET exon-14 skipping mutations ofter occurr in elderly patients that may be unfit for immunotherapy and/or chemotherapy, although they may still tolerate target therapy. Moreover, growing evidence suggest that MET inhibitors are a valuable option also as first-line treatment. Thus, we believe that the approval of MET inhibitors only for pretreated patients may limit the access to an active treatment for those elderly patients with metastatic MET-exon 14 mutant NSCLC that are unfit to receive first-line immunotherapy and/or chemotherapy.
At this regard, we discuss the case of a very elderly patient with MET-exon 14 mutant NSCLC that achieved a meaningful and durable benefit from first-line tepotinib, with an acceptable safety profile.”
For the article click here.
Source: Alessandro Inno/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023